Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | TACR1 | P25103 | 12/20 | 0.45 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.43 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.43 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.43 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.43 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.43 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14177570 | 1.00 | CYP2D6 (0.47) | CYP2D6TACR1CACNA1FCHRM5CACNA1D | |
| SCHEMBL14177610 | 1.00 | CYP2D6 (0.47) | CYP2D6TACR1CACNA1FCHRM5CACNA1D | |
| SCHEMBL14177611 | 1.00 | CYP2D6 (0.47) | CYP2D6TACR1CACNA1FCHRM5CACNA1D | |
| SCHEMBL14177576 | 1.00 | CYP2D6 (0.47) | CYP2D6TACR1CACNA1FCHRM5CACNA1D | |
| SCHEMBL14177693 | 0.88 | TACR1 (0.42) | TACR1CACNA1FCHRM5CACNA1DCACNA1S | |
| SCHEMBL14177692 | 0.88 | TACR1 (0.42) | TACR1CACNA1FCHRM5CACNA1DCACNA1S | |
| SCHEMBL14177632 | 0.84 | CYP26A1 (0.45) | CYP2D6TACR1 | |
| SCHEMBL4509005 | 0.84 | CYP26A1 (0.45) | CYP2D6TACR1 | |
| SCHEMBL5124798 | 0.84 | CYP26A1 (0.45) | CYP2D6TACR1 | |
| SCHEMBL14177563 | 0.84 | CYP26A1 (0.45) | CYP2D6TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
| EP-1864971-A1 | PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES | Takeda Pharmaceutical Company Limited (JP) | 2007-12-12 | — | — | EP | disclosed |
| EP-1864971-A1 | PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES | Takeda Pharmaceutical Company Limited (JP) | 2007-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | HSD11B1, HSD17B1, HSD11B2 | CYP2D6 469/4885TACR1 857/4885CACNA1F 2223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.